Detection of Cyclic Diguanylate G-Octaplex Assembly and Interaction with Proteins

Ori J. Lieberman1,2, Jeffery J. DeStefano1,2, Vincent T. Lee1,2*

1 Department of Cell Biology and Molecular Genetics, University of Maryland at College Park, College Park, Maryland, United States of America, 2 Maryland Pathogen Research Institute, College Park, Maryland, United States of America

Abstract

Bacterial signaling networks control a wide variety of cellular processes including growth, metabolism, and pathogenesis. Bis-(3’-5’)-cyclic dimeric guanosine monophosphate (cdiGMP) is a secondary signaling nucleotide that controls cellulose synthesis, biofilm formation, motility and virulence in a wide range of Gram-negative bacterial species. CdiGMP is a dynamic molecule that forms different tertiary structures in vitro, including a trans-monomer, cis-monomer, cis-dimer and G-octaplex (G8). Although the monomer and dimer have been shown to be physiologically relevant in modulating protein activity and transcription, the biological effects of the cdiGMP G8 has not yet been described. Here, we have developed a TLC-based assay to detect radiolabeled cdiGMP G8 formation. Utilizing the radiolabeled cdiGMP G8, we have also shown a novel inhibitory interaction between the cdiGMP G8 and HIV-1 reverse transcriptase and that the cdiGMP G8 does not interact with proteins from Pseudomonas aeruginosa known to bind monomeric and dimeric cdiGMP. These results suggest that the radiolabeled cdiGMP G8 can be used to measure interactions between the cdiGMP G8 and cellular proteins, providing an avenue through which the biological significance of this molecule could be investigated.

Introduction

Bis-(3’-5’)-cyclic dimeric guanosine monophosphate (cdiGMP) has become a key player in bacterial signaling networks since the first report describing its allosteric regulation of cellulose synthesis [1,2]. CdiGMP has now been implicated in several important aspects of microbial behavior and pathogenesis including inhibition of motility, activation of biofilm formation and regulation of virulence [3,4,5,6,7].

CdiGMP is a unique signaling dimucleotide because its two bases are rotatable with respect to each other allowing the molecule to take on a number of rotational conformations (rotamers). When made in the cell, cdiGMP affects cellular processes through direct binding to receptor proteins and RNAs [5,8,9]. Structural characterizations of cdiGMP interaction with macromolecules have shown to be specific for each rotamer. In the trans-monomer form of cdiGMP, the two bases are pointing away from each other (Fig. 1A). The trans-monomer form has been crystallized in complex with phosphodiesterases, including FimX, BhrP1, and YkuI which are responsible for the hydrolysis of cdiGMP to pGpG [10,11,12]. In the cis form, the two bases of the monomer are rotated 90˚ resulting in partially overlapping of the guanine bases (Fig. 1B). The cis-monomer binds both VCA0042, a PilZ-domain containing protein, as well as RNA riboswitches, such as Vc2 and GEMM [14,15,16]. In the cis-rotamer, cdiGMP can self-assemble to form higher order complexes [17,18,19]. The first complex is the cis-dimer in which one guanine from each monomer is sandwiched between the two guanines of the other monomer (Fig. 1C) [20]. The cis-dimer binds to diguanylate cyclases, such as PleD and WspR, the PilZ-domain protein PA4608 and a cdiGMP-regulated transcription factor, VpsT, in Vibrio cholerae [21,22,23,24]. The monomer and dimer forms of cdiGMP interconvert on a millisecond time scale [25]. In this manuscript, we will refer to these interchangeable forms as cdiGMP M/D. Another complex that can form from the cis rotamer is a G-quadruplex (G4) in which four cis monomers interact through base stacking and Hoogsteen base pairing [17,18,19,20] (Fig. 1D). As a result, the cdiGMP G4 complex has two stacked G-tetrad layers connected by four ribose-phosphate linkages. Finally, four additional cis-monomers can intercalate into the cdiGMP G4 complex to form a G-octaplex which we refer to as cdiGMP G8 (Fig. 1E) [19,25]. The backbones of each quadruplex are offset from each other in this structure (Fig. 1E) [19]. UV and NMR analyses of cdiGMP in solution suggest that, when complexed, only a small fraction of cdiGMP exists as a G4 but a larger fraction is complexed as a G8 [25]. The stability of the assembled cdiGMP G8 is similar to that of other known G-quadruplexes [26]. Together these studies demonstrate that many rotamers of cdiGMP are functionally recognized by cellular protein and RNA. However, the biological function of cdiGMP G8 has yet to be described. Developing biochemical assays to detect cdiGMP G8 interactions with protein and RNA will provide important insight into the ability of cdiGMP G8 to function in a biological setting.

G-quadruplex structures have recently come under scrutiny as they have been discovered in chromosomal DNA of both...
prokaryotes and eukaryotes [27,28,29]. In Neisseria gonorhoeae, G-quadruplex structures in the promoter of pilE have been shown to regulate antigenic variation [30]. In mammalian cells, G-quadruplex structures are present in telomere sequences to allow maintenance of chromosomal ends [31,32,33] and as transcription regulators of important oncogenes [34,35,36,37]. Proteins, such as TEBPalpha and TEBPbeta from Stylochius lemoae [38] and Hop1 from Saccharomyces cerevisae [39], promote formation of G-quadruplex structures. Other proteins, including the single stranded DNA binding protein UP1, are able to unfold these structures [40]. Through systematic evolution of ligands by exponential enrichment (SELEX) selection for protein binding nucleic acid aptamers, oligonucleotides have been described that are able to bind specific proteins with high affinity [41,42,43,44,45]. Some of these aptamers contain G-quadruplex domains, including the S4 and R1T G4 aptamers that bind human immunodeficiency virus (HIV) reverse transcriptase (RT) with dissociation constant (Kd) in the low nanomolar range and are potent inhibitors of RT activity [46,47]. The cdiGMP G8 is assembled from eight cdiGMP molecules and is considered an intermolecular G-quadruplex with four tetrad layers (Fig. 1E) [18,19]. The guanosine bases in cdiGMP G8 are either all anti or all syn [18,19]. The cdiGMP G8 cannot be defined by the orientation of their strands because its guanosine bases are not connected by the canonical sugar phosphate backbone as in DNA and RNA. Finally, G-quadruplexes can also be defined by the conditions that promote folding. The formation of the cdiGMP G8 is dependent on potassium cation and high cdiGMP concentration above one hundred micromolar [18,19,25].

In vitro, heating and slow cooling is also required for cdiGMP G8 formation [18]. Planar intercalators, such as flavin and thiazol orange, promote cdiGMP G8 formation at lower cdiGMP concentrations (<10 micromolar), without the need for heat, by stabilizing the intermolecular complex [52,53]. Thus, in vitro conditions that promote cdiGMP G8 assembly with planar intercalators can exist in the cell, indicating a possible role for cdiGMP G8 in vivo.

We set out to devise biochemical tools with which we could investigate whether cdiGMP G8 was able to interact with proteins specifically and modulate their activity. Here we show the generation of a radiolabeled cdiGMP G8 and its separation from radiolabeled cdiGMP M/D by thin layer chromatography. Using this newly labeled probe, we show that cdiGMP G8 can bind HIV RT specifically, but not the thrombin protease. Furthermore, we show that cdiGMP G8 is no longer recognized by known binding proteins of monomeric and cis-dimeric cdiGMP. Together, these results demonstrate that the potential

Figure 1. Cartoon depicting cdiGMP structures in solution. (A) The trans-monomer has the two bases oriented away from each other. (B) The cis-monomer has the two bases overlapping and is a precursor for higher order cdiGMP polymorphs. (C) The cis-dimer forms when two cis-monomers intercalate. This structure is stabilized by both π-stacking and hydrogen bonds between phosphates and bases. (D) The G-quadruplex (G4) forms when the bases from four cis-monomers interact via Hoogsteen base pairing and π-stacking. Monovalent cations, such as potassium, and high concentrations of cdiGMP promote this structure. The cation is located either in the middle of the G-tetrad plane or between G-tetrads and has been excluded here for clarity. (E) The G-octaplex (G8) forms when two G4 structures sandwich each other. This structure is stabilized by hydrogen bonding and base stacking. When potassium and high concentrations are present, the G8 is the predominant higher order rotamorf. doi:10.1371/journal.pone.0053689.g001
of cdiGMP G8 to have biological function can be investigated using these techniques.

Materials and Methods

Materials

HIV RT (HXB2 strain) was obtained from Worthington Biochemical Corporation (Lakewood, NJ USA). Thrombin protease was purchased from GE Healthcare. CdiGMP was purchased from Axxora. T4 polynucleotide kinase (PNK) was obtained from New England Biolabs. Deoxyribonucleotide triphosphates were from Roche Applied Sciences. Radiolabeled GTP and ATP were obtained from Perkin Elmer. Oligonucleotides were synthesized from Integrated DNA Technologies including PF1–5′-AGGAAGGCGTTAGGTCGATCCTCGGAAT-3′, S4–5′-CCGCTTGACCCCTT-CAGGCCGTGGTGGGGG-3′, 38 NT SELEX 5′-TATACCCTTTTCTCGGGTCAAAAGGACC-GAAGGGGGGGG-3′, TBA25 5′-GGTGTGTTGGTTGGG-3′. Ten (10) kDa size exclusion columns were obtained from VWR. Chemicals were purchased from Sigma-Aldrich Co., Thermo Fisher Scientific, Inc., or VWR Scientific, Inc.

Protein Purification

_P. aeruginosa_ cdiGMP M/D binding protein (maltose binding protein [MBP], MBP-Alg44, MBP-PelD ATM, WspR D70E, RocR, MBP-PA0012, MBP-PA3353, MBP-PA4324, and MBP-PilZ) were cloned, overexpressed and purified as described in [54]. RocR, MBP-PA0012, MBP-PA3353, MBP-PA4324, and MBP-PilZ protein (MBP), MBP-Alg44, MBP-PelD

D protein (maltose binding protein (MBP), MBP-Alg44, MBP-PelD)

for each sample was determined using a Thermo Scientific NanoDrop 8000. UV-vis spectrometer was blanked with K⁺ buffer (10 mM Tris base pH 7.9, 100 mM KCl, 5 mM MgCl₂).

Thin Layer Chromatography (TLC)

Proteins and ligands at the indicated concentrations (³²P-cdiGMP, ³²P-cdiGMP G8 and ³²P-labeled oligonucleotides) were mixed and incubated for 10 minutes at room temperature ([54,60]). For cdiGMP M/D binding protein panels, 9.8 μM WspR D70E, 4 μM MBP-PelD, 9.4 μM MBP-Alg44, 6 μM RocR, 3.9 μM MBP-PA0012, 1 μM MBP-PA3353, 3.8 μM MBP-PA4324, 13 μM MBP-PilZ, 960 nM HIV RT, and 10 μM MBP were used. For competition and IC₅₀ binding assays, the indicated concentration of unlabeled competitor was added to the reaction at the same time. K₅₀ was obtained by holding ³²P-cdiGMP concentration at 500 nM and serially diluting protein concentration. Reaction mixtures (2.5 μL) were spotted on dry nitrocellulose. Membrane was dried and imaged using a Fujifilm FLA-7000 phosphorimager and analyzed with Multigauge software. Fraction bound was calculated according to [54] or as specified in the text.

Differential Radial Capillary Action of Ligand Assay (DRAcALA)

Proteins and ligands at the indicated concentrations (³²P-cdiGMP, ³²P-cdiGMP G8 and ³²P-labeled oligonucleotides) were mixed and incubated for 10 minutes at room temperature ([54,60]). For cdiGMP M/D binding protein panels, 9.8 μM WspR D70E, 4 μM MBP-PelD, 9.4 μM MBP-Alg44, 6 μM RocR, 3.9 μM MBP-PA0012, 1 μM MBP-PA3353, 3.8 μM MBP-PA4324, 13 μM MBP-PilZ, 960 nM HIV RT, and 10 μM MBP were used. For competition and IC₅₀ binding assays, the indicated concentration of unlabeled competitor was added to the reaction at the same time. K₅₀ was obtained by holding ³²P-cdiGMP concentration at 500 nM and serially diluting protein concentration.Reaction mixtures (2.5 μL) were spotted on dry nitrocellulose. Membrane was dried and imaged using a Fujifilm FLA-7000 phosphorimager and analyzed with Multigauge software. Fraction bound was calculated according to [54] or as specified in the text.

HIV RT Inhibition Assays

Assays to determine the effect of cdiGMP M/D and cdiGMP G8 complexes on RT activity were conducted essentially as described in [61]. Reactions contained substrate (1:1:2 primer (5′-TCCCCGGGTACCAGGCTGATCCTCGGCCCTATAG-3′);template (5′-TTGTAATAGCTACACTTAFAGGCG-GAATTCGAGGCTGATCCTCGGCCCTATAG-3′);final concentr in reactions was 50 nM in 5′-³²P end-labeled primer). HIV-1 RT (0.25 nM), 50 nM Tris-HCl (pH = 8); 1 mM DTT, 80 mM KCl (or NaCl), 6 mM MgCl₂, 100 μM dNTPs and 0.1 μg/μL BSA. Two types of assays were used, a time course in the presence of a fixed amount of the various cdiGMP forms or assays using a fixed 5 minute time point and increasing amounts of cdiGMP forms. Values for half-maximal inhibition (IC₅₀) were determined from the fixed time point assays as described in [61]. The amounts of the various cdiGMP forms used in the assays are shown in the figures and figure legends.
WspR Activity Assays

WspR (D70E) (1.2 μM), α-32P-GTP, and 500 μM of the indicated inhibitor were incubated at room temperature for the specified amount of time. Reactions were then mixed 1:3 with 50 μM ethylenediaminetetraacetic acid (EDTA) and heated for 5 minutes at 82°C [1,55]. Sample (0.6 μL) was then spotted on PEI-cellulose TLC plates and allowed the dry. These spots were separated with elution buffer as described above, dried and imaged as described above. Fraction cdiGMP formed was determined by measuring the intensity of the cdiGMP band and dividing by the total intensity. Measurements were made with Multigauge software.

Results

Higher Order Molecular Complexes of cdiGMP can be Detected by Thin-layer Chromatography

TLC is able to distinguish GTP, cdiGMP M/D, and pGpG [1,56,57,58,62]. We were interested in seeing whether TLC could also separate the 32P-cdiGMP G8 from the 32P-cdiGMP M/D. Generation and separation of a radiolabeled cdiGMP G8 allowed for biochemical analysis of the behavior of this molecule. To investigate whether the 32P-cdiGMP G8 could be separated from the 32P-cdiGMP M/D, four mixtures of cdiGMP were prepared under different conditions, spotted on PEI-coated TLC plates, and separated as indicated in Materials and Methods. Previous studies of cdiGMP G8 synthesis suggest that, in the absence of intercalators, G8 formation is driven by two key parameters: 1. cation type and 2. cdiGMP concentration [18,19]. We asked whether cdiGMP G8 formation is only observed in the presence of K+ and high concentrations of cdiGMP when assayed by TLC. At nanomolar concentrations of cdiGMP in buffer containing K+, 32P-cdiGMP migrated with an Rf value of 0.2 (Fig. 2A, lane 1). In K+ buffer and at 500 μM cdiGMP, ~90% of the radiolabelled cdiGMP migrated with an Rf of 0.06 with a minor species migrating at an Rf of 0.2 (Fig. 2A, lane 2). In Na+ buffer with nanomolar cdiGMP concentrations, 32P-cdiGMP migrated at an Rf of 0.2 (Fig. 2A, lane 3). In Na+ buffer with 500 μM cdiGMP, ~40% of 32P-cdiGMP migrated with an Rf value of 0.06 while the remainder migrated to the more mobile Rf value of 0.2 (Fig. 2A, lane 4).

The conditions that promote cdiGMP G8 formation resulted in the appearance of a slower migrating species with an Rf value of 0.06 when assayed by TLC [18,19,25].

Although we expected the 32P-cdiGMP to form G8 complexes in the presence of K+ (Fig. 1A, lane 2), a substantial portion of the 32P-cdiGMP in Na+ buffer with high cdiGMP concentration was also converted to a slower migrating species (Fig. 2A, lane 4). Since cdiGMP G8 is stable, it is resistant to disassembly into M/D forms upon dilution in water [25]. In fact, on the time scale of our experiments, we observed no interconversion between the cdiGMP G8 species and M/D species when analyzed by TLC (Fig. S1). To test the G8 status of the slower migrating species observed in the Na+ buffer, we serially diluted both Na+32P-cdiGMP G8 and K+32P-cdiGMP G8 in water and measured the amount of 32P-cdiGMP G8 present by TLC after 10 minutes incubation at room temperature (Fig. 2B). Diluting the Na+32P-cdiGMP G8 by two-fold led to disassembly of 32P-cdiGMP G8 into 32P-cdiGMP M/D while the K+32P-cdiGMP G8 was stable even when diluted 32-fold (Fig. 2B). These results demonstrate that the slower migrating species observed in the K+ buffer is indeed assembled cdiGMP G8.

Previous analyses of cdiGMP mixtures have shown that the cdiGMP G8 has unique spectral properties in the ultraviolet spectrum with a maximum absorbance at 256 nm and a shoulder at 293 nm [18]. In contrast, the UV spectrum of cdiGMP M/D is similar to that of GTP with a maximum absorbance at 253 nm and a shoulder at 280 nm [18]. These previous studies also showed that cdiGMP G8 has a reduced maximum absorbance compared to the cdiGMP M/D [18] and the amount of cdiGMP G8 present in a sample inversely correlates to the ratio of the absorbance at 276 nm and 289 nm [25]. To determine if the cdiGMP G8 we prepared has similar spectroscopic properties, UV spectra were obtained for the sample of 500 μM cdiGMP heated and slowly cooled in K+ to assemble cdiGMP G8 and a sample of 500 μM cdiGMP in K+ that was not heated and remained cdiGMP M/D (Fig. 2C). We observed peak absorbance for the cdiGMP M/D at 253 nm while the cdiGMP G8 had a peak at 256 nm (Table 1). The maximum absorbance of the cdiGMP M/D was 0.732±0.019 while that of the cdiGMP G8 was 0.560±0.005 (Table 1). The cdiGMP M/D had an A276/A289 of 2.08±0.02 compared with an A276/A289 of 1.50±0.01 for the cdiGMP G8 (Table 1). This provides further confirmation that the cdiGMP G8 is present in samples prepared with K+ and runs with an Rf of 0.06 on TLC. Together these results show that the cdiGMP G8 can be radiolabeled and detected by TLC.

Specificity of cdiGMP G8 Binding to G-quadruplex Binding Proteins

Oligonucleotide aptamers identified for HIV RT and thrombin protease by SELEX revealed sequences containing G-quadruplexes. The HIV RT binds parallel G-quadruplexes while thrombin protease binds anti-parallel G-quadruplexes [41,42,43,44,45]. To test whether cdiGMP G8 can be directly bound by either class of G-quadruplex binding proteins, we employed the same four mixtures described in Fig. 2A using the differential radial capillary action of ligand assay (DRAcALA) [54]. CdiGMP G8 bound RT (Fig. 3A, lane 2). In contrast, cdiGMP M/D in K+ buffer did not bind HIV RT (Fig. 3A, lane 1). CdiGMP prepared in Na+ with either low or high cdiGMP concentration was not able to bind HIV RT (Fig. 3A, lanes 3 and 4, respectively). These results suggest that the cdiGMP G8 binds to HIV-1 RT, while the cdiGMP M/D does not. Since HIV RT and thrombin protease bind G-quadruplex aptamers with parallel and anti-parallel structures, respectively [26], we asked whether cdiGMP G8 mimics either parallel, anti-parallel, or both configurations as it lacks the canonical sugar phosphate backbone. Neither the cdiGMP G8 nor the cdiGMP M/D bound thrombin protease (Fig. 3B). As a control, thrombin did bind the specific anti-parallel G-quadruplex aptamer TBA25 (Fig. 3B) [40,49]. These results suggest that cdiGMP G8 is able to bind proteins as a conformational mimic to the parallel G-quadruplex aptamer.

Relative Affinity of cdiGMP G8 Binding to HIV RT

cdiGMP G8 could bind HIV RT in the primer-template binding site or elsewhere on the protein. To distinguish between these two possibilities, we took advantage of available aptamers S4, 38 NT SELEX, and PF1 that bind in the primer-template binding site of HIV RT with dissociation constants of approximately 1, 6, and 125 nM, respectively [47,61,63,64]. By competitive binding assays using DRAcALA, addition of 10X molar excess of each unlabeled aptamer strongly reduced the interaction of RT and 32P-cdiGMP G8 [54,60] (Fig. 4A). In the absence of competitor, the 32P-cdiGMP G8 was able to bind to RT. This suggests that the 32P-cdiGMP G8 binds at the primer-template binding site.
The affinity of cdiGMP G8 for HIV RT was determined using two methods. First, we determined the IC₅₀ values for the inhibition of radiolabeled PF1 binding to RT by unlabeled cdiGMP G8 or PF1 aptamer. Unlabeled PF1 inhibited cdiGMP binding with an IC₅₀ of 4 μM and unlabeled cdiGMP G8 inhibited with an IC₅₀ of 12 μM, suggesting that the cdiGMP G8 may bind with approximately 3 times lower affinity to RT (Fig. 4B). Based on the dissociation constant (Kₐ) of the PF1 aptamer for RT (~ 125 nM) [61], the Kₐ of the cdiGMP G8 for HIV RT can be approximated as 400 nM. The Kₐ of the cdiGMP G8 and RT was also determined by direct binding using DRAcALA. By serially diluting the protein concentration and limiting cdiGMP G8 concentrations to 500 nM, the Kₐ can be obtained from the plot of fraction bound against the protein concentration. The Kₐ of this interaction was 700±100 nM, which is similar to the relative affinity calculated from the competitive binding assays (Fig. 4C).

CdiGMP G8 Inhibits HIV RT Activity

G-quadruplex aptamers are able to bind to RT and inhibit RT activity with IC₅₀ values in the nanomolar range [46,47,61,63,64]. Having demonstrated that the cdiGMP G8 binds to HIV RT at the primer-template site, we asked whether the cdiGMP G8 was able to similarly inhibit RT function. To test this, an RT primer extension assay was used [61]. Reactions included either KCl or NaCl (80 mM final concentration) depending on which cation was used in the preparation of cdiGMP G8 material. Controls with no cdiGMP or with cdiGMP M/D were also conducted. A pilot experiment showed that cdiGMP G8 prepared in K⁺ significantly inhibited RT activity when present in reactions at approximately 80 μM (data not shown). This level was chosen for the examination of various cdiGMP preparations (see Fig. 2) over a 20 minute time course assay as shown (Fig. 5A). M/D forms did not affect RT activity in reactions containing either Na⁺ or K⁺. CdiGMP G8 prepared in Na⁺ buffer showed some inhibition while material prepared in K⁺ buffer was a more potent inhibitor leading to about a 3-fold reduction in RT activity. These results suggest that the cdiGMP G8 complexes are responsible for inhibition as formation of these complexes is enhanced by K⁺, whereas the complexes formed in Na⁺ buffer disassembled into M/D upon dilution. A second set of experiments was conducted in which reactions were titrated with cdiGMP G8 complexes prepared in K⁺ or Na⁺ (Fig. 5B). This approach allowed us to determine an IC₅₀ value of 28±7 μM (ave. of 3 exp. ± standard deviation) for cdiGMP G8 prepared in K⁺. A value for material prepared in Na⁺ could not be determined as the level of inhibition was too low. Although the cdiGMP G8 inhibited RT with approximately 1000X less potency than the aptamers S4, 38 NT SELEX and PF1 [47,61,63,64], equimolar amounts of cdiGMP M/D showed no inhibition. These experiments establish the first report of cdiGMP G8 modulating protein function separately from cdiGMP M/D forms and suggest that the radiolabeled cdiGMP G8 can be used to biochemically investigate the physiological significance of the molecule.

Table 1. Summary of UV-Vis absorbance measurements for the cdiGMP G8 and the cdiGMP M/D.

| Sample      | Wavelength (nm) | 1.0 mm Absorbance |
|-------------|-----------------|--------------------|
| cdiGMP M/D  | 253             | 0.732±0.019        |
| cdiGMP G8   | 256             | 0.560±0.005        |
| Absorbance at 276 nm |       |                    |
| Sample      | 1.0 mm Absorbance |                |
| cdiGMP M/D  | 0.453±0.012     |                    |
| cdiGMP G8   | 0.305±0.004     |                    |
| Absorbance at 289 nm |       |                    |
| Sample      | 1.0 mm Absorbance |                |
| cdiGMP M/D  | 0.218±0.006     |                    |
| cdiGMP G8   | 0.203±0.004     |                    |
| A₂₇₆/A₂₈⁹   |                |                    |
| Sample      | A₂₇₆/A₂₈⁹       |                    |
| cdiGMP M/D  | 2.08±0.02       |                    |
| cdiGMP G8   | 1.50±0.01       |                    |

doi:10.1371/journal.pone.0053689.t001

Figure 2. Thin layer chromatography separates 32P-cdiGMP G8 from 32P-cdiGMP M/D. (A) Four mixtures of 32P-cdiGMP were heated, cooled, spotted on PEI-cellulose TLC plates, and separated with a mobile phase of 0.9 M KH₂PO₄ and 40% (v/v) saturated NH₄PO₄. 32P-cdiGMP was prepared in buffer containing K⁺ (Lane 1 and 2) or Na⁺ (Lane 3 and 4) with no additional cdiGMP (Lane 1 and 3) or 500 μM cdiGMP (Lane 2 and 4). The retention factor (Rf) is indicated on the left of the TLC. (B) Samples in lane 2 and 4 from Panel A were two-fold serially diluted in water and allowed to incubate at room temperature for ten minutes. Samples were then spotted and separated by TLC as in (A) and the total 32P-cdiGMP G8 (Rf = 0.06) was quantified and plotted. The first sample is undiluted and the dilution factor for the other samples is indicated on the X-axis. (C) UV-vis spectra of cooled, spotted on PEI-cellulose TLC plates, and separated with a mobile phase of 0.9 M KH₂PO₄ and 40% (v/v) saturated NH₄PO₄. 32P-cdiGMP was prepared in buffer containing K⁺ or Na⁺ (Lane 1 and 2) or Na⁺ (Lane 3 and 4) with no additional cdiGMP (Lane 1 and 3) or 500 μM cdiGMP (Lane 2 and 4). The retention factor (Rf) is indicated on the left of the TLC. (Lane 1 and 2) or NaCl (80 mM final concentration) depending on which cation was used in the preparation of cdiGMP G8 material. Controls with no cdiGMP or with cdiGMP M/D were also conducted. A pilot experiment showed that cdiGMP G8 prepared in K⁺ significantly inhibited RT activity when present in reactions at approximately 80 μM (data not shown). This level was chosen for the examination of various cdiGMP preparations (see Fig. 2) over a 20 minute time course assay as shown (Fig. 5A). M/D forms did not affect RT activity in reactions containing either Na⁺ or K⁺. CdiGMP G8 prepared in Na⁺ buffer showed some inhibition while material prepared in K⁺ buffer was a more potent inhibitor leading to about a 3-fold reduction in RT activity. These results suggest that the cdiGMP G8 complexes are responsible for inhibition as formation of these complexes is enhanced by K⁺, whereas the complexes formed in Na⁺ buffer disassembled into M/D upon dilution. A second set of experiments was conducted in which reactions were titrated with cdiGMP G8 complexes prepared in K⁺ or Na⁺ (Fig. 5B). This approach allowed us to determine an IC₅₀ value of 28±7 μM (ave. of 3 exp. ± standard deviation) for cdiGMP G8 prepared in K⁺. A value for material prepared in Na⁺ could not be determined as the level of inhibition was too low. Although the cdiGMP G8 inhibited RT with approximately 1000X less potency than the aptamers S4, 38 NT SELEX and PF1 [47,61,63,64], equimolar amounts of cdiGMP M/D showed no inhibition. These experiments establish the first report of cdiGMP G8 modulating protein function separately from cdiGMP M/D forms and suggest that the radiolabeled cdiGMP G8 can be used to biochemically investigate the physiological significance of the molecule.
CdiGMP G8 does not Bind Pseudomonas aeruginosa cdiGMP M/D Binding Proteins in vitro

CdiGMP is a secondary signaling molecule that regulates the behavior of many bacterial species [1, 76-78, 69]. Using the radiolabeled cdiGMP G8, we were interested in whether the cdiGMP G8 can interact with proteins known to bind cdiGMP M/D. A panel of binding proteins was tested including the WspR diguanylate cyclase that binds the cis cdiGMP dimer, the RocR phosphodiesterase that binds trans monomeric cdiGMP, PelD that binds cdiGMP at a site that resembles the inhibitory site (I-site) found in many diguanylate cyclases and PilZ-domain containing proteins that bind either monomeric or dimeric cdiGMP [22, 75-78, 69]. The ability of purified proteins to interact with either 32P-cdiGMP M/D or 32P-cdiGMP G8 were assessed by DRaCALA [54]. Interestingly, upon spotting the radiolabeled G8 mixture with no protein, two concentric circles were observed (Fig. S2). We obtained a diffuse and uniform spot on nitrocellulose upon spotting the 32P-cdiGMP M/D without protein (Fig. S3B). An in-depth explanation of this phenomenon and rationale behind the calculation of 32P-cdiGMP G8 bound can be found in the supplemental material (Fig. S2, S3, S4). Our calculations suggest that none of the bacterial cdiGMP M/D binding proteins bound 32P-cdiGMP G8 in contrast to the HIV RT positive control (Fig. 6A). P. aeruginosa cdiGMP M/D binding proteins bound 32P-cdiGMP M/D, whereas HIV RT did not (Fig. 6B). As a negative control for binding, maltose binding protein (MBP) and PilZ protein (PA2960), which are known not to bind 32P-cdiGMP M/D [69], also do not bind 32P-cdiGMP G8. These results indicate that cdiGMP G8 structures are no longer recognized by the same binding pockets that interact with cdiGMP M/D, and provide evidence that DRaCALA is able to measure protein binding to the cdiGMP G8.

Figure 3. CdiGMP G8 binds HIV-1 reverse transcriptase, a parallel G-tetrad binding protein, but not thrombin protease, an anti-parallel binding protein. (A) HIV-1 RT (960 nM) was incubated with cdiGMP heated in 4 nM cdiGMP (−) and 500 μM cdiGMP (+) in the salt indicated. Binding was analyzed via DRaCALA. (B) Thrombin protease (8 μM) was incubated with 32P-cdiGMP G8 (lane 1), 32P-cdiGMP M/D (lane 2), 32P-TBA25 (lane 3) and binding was analyzed via DRaCALA. 32P-cdiGMP G8 (lane 4) and 32P-TBA25 (lane 5) were spotted without protein as negative controls. doi:10.1371/journal.pone.0053689.g003

Figure 4. CdiGMP G8 binds to RT specifically with sub-micromolar affinity. (A) 32P-cdiGMP G8 (500 nM) was incubated with 960 nM HIV-1 RT and 5 μM indicated competitor and binding was analyzed by DRaCALA. (B) 32P-PF1 (5 nM) was incubated with 960 nM HIV-1 RT and competitor at the indicated concentrations. Binding was analyzed via DRaCALA and data was analyzed by Prism Software to obtain IC50 values. (C) 32P-cdiGMP G8 (500 nM) was incubated with indicated concentration of HIV-1 RT and binding was assayed via DRaCALA. The data was plotted and analyzed using Prism Software. doi:10.1371/journal.pone.0053689.g004
CdiGMP G8 is Unable to Inhibit Diguanylate Cyclase Activity

The diguanylate cyclase WspR (PA3702) is allosterically inhibited by the cdiGMP cis-dimer at a regulatory I-site on the protein [22]. The I-site consists of a RxxD motif that is found in a wide range of diguanylate cyclases, which suggests that this type of inhibition is functionally conserved. An activation domain mutant version (D70E) of wspR has been previously described to allow for constitutive diguanylate cyclase activity [55]. We performed a time course experiment to determine the optimal time to observe cdiGMP M/D mediated inhibition of WspR.

At three hours of incubation, WspR catalyzed the maximal conversion of 32P-GTP to 32P-cdiGMP (Fig. 7A). In the presence of 500 μM cdiGMP M/D, none of the 32P-GTP was converted to 32P-cdiGMP (Fig. 7A). To investigate the ability of the cdiGMP G8 to alter WspR activity, we assayed for inhibition of varying concentrations of cdiGMP G8 or cdiGMP M/D at the three hour time point. Inhibition of WspR by cdiGMP M/D was concentration dependent with a reduction of activity by 28.3-fold at 500 μM (Fig. 7B). In contrast, the cdiGMP G8 reduced WspR activity by 2.2-fold (Fig. 7B). Residual inhibition can be attributed to remaining cdiGMP M/D in the cdiGMP G8 reaction mixture. Thus, cdiGMP G8 is unable to bind WspR or allosterically inhibit cdiGMP synthesis as observed for the cdiGMP M/D, confirming the findings of our binding studies that show that the cdiGMP G8 does not interact with the diguanylate cyclase WspR.

Discussion

CdiGMP is a second messenger that controls biofilm formation, virulence, motility and other metabolic processes in a number of bacterial species. In vitro, cdiGMP can form higher order molecular structures including G8 when cdiGMP reaches concentrations greater than 100 μM, potassium is present, and the sample is heated and slowly cooled [18,19,25]. Although the cdiGMP G8 has been shown to form in vitro, no studies have confirmed its presence under physiological conditions. Planar intercalators, such as flavin rings, however, promote cdiGMP G8 formation at 1–10 μM concentrations of cdiGMP, without the requirement for heat, providing a mechanism through which the cdiGMP G8 may form in the cell [52,53]. The biological role of cdiGMP G8 can be demonstrated in three ways: 1. visualizing cdiGMP G8 formation in vivo, 2. purifying cdiGMP G8 from the cell and determining its structure in vitro, or 3. identifying proteins that specifically interact with the cdiGMP G8 but not cdiGMP M/D. At this current time, visualization or extraction of cdiGMP G8 is not technically feasible. So, we set out to develop novel biochemical approaches to assess cdiGMP G8 interactions with proteins. These techniques could allow for investigation of the biological significance of this intermolecular complex.
Currently, the assembly of cdiGMP into G8 has been demonstrated by the appearance of a characteristic positive shift at 250 nm, a negative shift at 280 nm, an extremely strong positive shift at 215 nm and moderate positive shift at 309 nm when detected by CD spectroscopy [18]. This approach cannot simultaneously detect and quantitate both the M/D and G8 species of cdiGMP. Furthermore, binding interactions of unlabeled cdiGMP G8 with proteins would be difficult to detect by CD, due to interference from protein signals. We utilized thin layer chromatography (TLC) to measure radiolabeled cdiGMP G8 formation in vitro. TLC was able to separate the 32P-cdiGMP G8 from 32P-cdiGMP M/D both qualitatively and quantitatively. Additionally, we have demonstrated that heating and cooling of cdiGMP is necessary for potassium-dependent G8 formation using this technique. This is an important development as assessing 32P-cdiGMP G8 formation in vitro hinges on techniques that utilize easily detected radioactive tracers. Furthermore, validating a method that can measure the formation of cdiGMP G8 is an important step in finding interacting proteins in the cell.

How the cdiGMP G8 behaves in a biological setting will provide insight into its potential as a physiologically relevant complex. Because no cdiGMP G8 binding proteins have been described, we were first interested in finding a protein that specifically interacts with this complex. Previously, proteins such as HIV RT and thrombin protease have been shown to bind G-quadruplex structures [44,45]. We hypothesized that these proteins may also bind to cdiGMP G8. We have shown here that the cdiGMP G8 binds to HIV-1 RT at the primer-template binding site with a K_d of approximately 400–700 nM. This is the first report, to our knowledge, of a cdiGMP G8 binding protein. This binding interaction can be utilized in future studies of the cdiGMP G8. G-quadruplexes can assemble either parallel or anti-parallel configurations depending on the relative arrangement of the sugar phosphate backbone [26]. We asked whether cdiGMP G8, a symmetric molecule which lacks orientation derived from the sugar-phosphate backbone, acquires properties of parallel or anti-parallel G-quadruplex structures. All previously described G-quadruplex aptamers that interact with HIV RT have been parallel-folded G-quadruplexes [61]. These RT aptamers (e.g., PF1) bind at or near the primer-template binding pocket based on their ability to compete for a common binding site with the primer-template aptamer, 38 NT SELEX [61]. The fact that the cdiGMP G8 can displace PF1 suggests it binds at the same site. Further, the fact that cdiGMP G8 binds RT suggests that it behaves as a parallel G-quadruplex. We also indirectly tested whether the cdiGMP G8 takes on an anti-parallel conformation by measuring cdiGMP G8 interaction with thrombin protease, a protein that binds an anti-parallel G-quadruplex structure in the TBA aptamer. The cdiGMP G8 did not bind to thrombin. These results suggest that, despite lacking the directionality imparted by a sugar-phosphate backbone, cdiGMP G8 can take on properties of one specific configuration of G-quadruplex. These insights provide evidence that cdiGMP G8 is a unique ligand that may mediate biological processes through parallel G-quadruplex binding proteins.

Different conformations of cdiGMP structures have been shown to play a biological role in cell signaling. In P. aeruginosa, cdiGMP binds to a wide variety of binding pockets including the PelD, RexD, and PilZ domain [22,53,69,70]. We wondered whether the cdiGMP G8 could bind to proteins with these domains. Using the radiolabeled cdiGMP G8 that we generated, we assayed a panel of cdiGMP M/D proteins for their ability to bind the cdiGMP G8. CdiGMP G8 did not bind to any of the cdiGMP M/D binding proteins. This is the first time, to our knowledge, that the cdiGMP G8 has been shown to be a biochemically distinct ligand from the cdiGMP M/D. Future studies of the cdiGMP G8 can focus on proteins other than previously described cdiGMP M/D proteins. Finally, showing that the radiolabeled cdiGMP G8 that we generated specifically interacts with G-quadruplex binding proteins but not cdiGMP M/D binding proteins further supports the idea that this is a viable approach in searching for cognate cdiGMP G8 binding proteins.

Supporting Information

Figure S1 CdiGMP G8 and cdiGMP M/D do not interchange on the experimental timescale as measured by TLC. (A) Scanned TLC plate of 0.6 μL aliquots of cdiGMP G8 taken at time points indicated. Samples were separated as described in the Materials and Methods. (B) Graph of quantified fraction cdiGMP G8 and fraction cdiGMP M/D over the time scale of the experiments. Error bars indicate the standard deviation of two individual experiments. (C) TLC plate of aliquots from cdiGMP M/D taken from sample at indicated times. (D) Quantified fraction cdiGMP G8 and fraction cdiGMP M/D at indicated time points. (TIF)
M/D spot (2.5 μL) on nitrocellulose. (C) Equation used to calculate the fraction (F) of $^{32}$P-cdiGMP G8 in the mixture.

Figure S3 Maltose binding protein (MBP) can be used as a standard to fraction 3$^{2}$P-cdiGMP G8 bound by other proteins. (A) Schematic representing appearance of DRaCALA spot upon addition of protein to the reaction mixture. Inner circle contains sequestered ligand. (B) Imaged DRaCALA spots (2.5 μL) of reactions that included MBP, PA3353, and RT. The line appearing through the image is used for the intensity vs. position plot in (C). (C) Intensity vs. position plots across the black lines in Fig. S2B for binding reactions that included MBP, PA3353, and RT. (D) Cartoon representing idealized intensity vs. position diagrams MBP, PA3353, and RT binding reactions.

Figure S4 Equations used to calculate fraction 3$^{2}$P-cdiGMP G8 bound by cdiGMP M/D binding proteins. (A) Equations used to subtract free 3$^{2}$P-cdiGMP M/D from the cdiGMP G8 bound by cdiGMP M/D binding proteins. (B) contains sequestered ligand. (C) appearing through the image is used for the intensity vs. position of reactions that included MBP, PA3353, and RT. The line diagrams MBP, PA3353, and RT binding reactions.

Text S1.

Acknowledgments

The authors wish to acknowledge S. Watt, K. Roelofs and M. Wu for supplying reagents, G. Crimmins and R. Corrigan for insightful discussions and R. Stewart for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: OJL, JJD VTL. Performed the experiments: OJL, JJD. Analyzed the data: OJL, JJD VTL. Contributed reagents/materials/analysis tools: OJL, JJD. Wrote the paper: OJL, JJD VTL.

References

1. Ross P, Weinhouse I, Aloni Y, Michaeli D, Weinberger-Ohana P, et al. (1987) Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 325: 279–281.
2. Ross P, Aloni Y, Weinhouse C, Michaeli D, Weinberger-Ohana P, et al. (1985) An unusual guanylyl oligonucleotide regulates cellulose synthesis in Acetobacter xylinum. FEBS Lett 196: 191–196.
3. Jenal U (2004) Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria? Curr Opin Microbiol 7: 185–193.
4. Henger R (2009) Principles of c-di-GMP signalling. Nat Rev Microbiol 7: 263–273.
5. Schirner T, Jenal U (2009) Structural and mechanistic determinants of c-di-GMP signalling. Nat Rev Microbiol 7: 724–735.
6. Römöling U, Gomesky M, Galperin MY (2005) c-Di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 57: 629–639.
7. Römöling U, Summ R (2009) Prevailing concepts of c-di-GMP signalling. Contrib Microbiol 16: 161–161.
8. Smith KD, Shahana CA, Moore EI, Simon AC, Strobel SA (2009) Structural basis of activity and allosteric control of diguanylate cyclase. Proceedings of the National Academy of Sciences of the United States of America 106: 17049–17049.
9. De N, Navarro MV, Raghavan RV, Sondermann H (2009) Determinants for the sequestration and autoinhibition of the diguanylate cyclase response regulator WspR. J Biol Chem 393: 619–633.
10. Habazettl J, Allan MG, Jenal U, Grzeszcz S (2011) Solution Structure of the PiZ Domain Protein PA6608 Complex with Cyclic di-GMP Identifies Charge Clustering as Molecular Readout. Journal of Biological Chemistry 286: 14304–14314.
11. Krasteva PV, Fong JC, Shikama NJ, Beyhan SA, Navarro MV, et al. (2010) Vibrion cheddarae VpsI regulates matrix production and motility by directly sensing cyclic di-GMP. Science 327: 986–989.
12. Gentner M, Allan MG, Zahringer F, Schirner T, Grzeszcz S (2012) Oligomer formation of the bacterial second messenger c-di-GMP: reaction rates and equilibrium constants indicate a monomeric state at physiological concentration. Journal of the American Chemical Society.
13. Keniry MA (2000) Quadruplex structures in nucleic acids. Biopolymers 56: 123–146.
14. Fry M (2007) Tetraplex DNA and its interacting proteins. Front Biosci 12: 4336–4351.
15. Kendrick S, Hurley LH (2010) The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements. Pure Appl Chem 82: 1609–1621.
16. Qin Y, Hurley LH (2006) Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochemistry 90: 1149–1171.
17. Calhoon LA, Seffert HS (2009) An Alternative DNA Structure Is Necessary for FimL Antigenic Variation in Neisseria gonorrhoeae. Science 325: 764–764.
18. Parkinson GN, Lee MP, Neidle S (2002) Crystal structure of parallel quadruplexes from human telomeric DNA. Nature 417: 876–880.
19. Smith WD, Pleij J (1992) Quadruplex structure of Oxytricha termiticola telomeric DNA oligonucleotides. Nature 356: 164–168.
20. Horvath MP, Schultz SC (2003) G-quartets in a 1.86 A resolution structure of an Oxytricha nova telomeric protein-DNA complex. J Mol Biol 310: 367–377.
21. Siddiqui-Jain A, Grant CL, Bearss DJ, Hurley LH (2002) Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A 99: 11593–11598.
22. Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 108–108.
23. Bansalramaniam S, Hurley LH, Neidle S (2011) Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov 10: 261–275.
24. Brooks TA, Kendrick S, Hurley LH (2010) Making sense of G-quadruplex and i-motif functions in oncogene promoters. FEBS J 277: 3459–3469.
25. Paeschke K, Juranek S, Simonsson T, Hempel A, Rhodes D, et al. (2008) Telomerase recruitment by the telomere end binding protein-beta facilitates G-quadruplex DNA unfolding in ciliates. Nat Struct Mol Biol 15: 598–604.

PLOS ONE | www.plosone.org 9 January 2013 | Volume 8 | Issue 1 | e53689
54. Roelofs KG, Wang J, Sintim HO, Lee VT (2011) Differential radial capillary action of ligand assay for high-throughput detection of protein-metabolite interactions. Proc Natl Acad Sci U S A 108: 15520–15533.

55. Lee VT, Matsewh JM, Kesler JL, Hyodo M, Hayakawa Y, et al. (2007) A cyclic-di-GMP receptor required for bacterial exopolysaccharide production. Mol Microbiol 65: 1474–1484.

56. Randerath K (1964) Separation of the constituent nucleotides of nucleic acids on ion-exchange thin-layers. Experientia 20: 406–407.

57. Bochner BR, Ames BN (1982) Complete Analysis of Cellular Nucleotides by Two-Dimensional Thin Layer Chromatography. Journal of Biological Chemistry 257: 9759–9769.

58. Paul R, Weiser S, Amiot NC, Chan C, Schirmer T, et al. (2004) Cell Cycle-Dependent Dynamic Localization of a Bacterial Response Regulator with a Novel Di-Guanylate Cyclase Output Domain. Genes & Development 18: 715–727.

59. Christen M, Christen B, Fokker M, Schauerte A, Jena U (2005) Identification and Characterization of a Cyclic Di-GMP-Specific Phosphodiesterase and Its Allosteric Control by GTP. Journal of Biological Chemistry 280: 30829–30837.

60. Donaldson GP, Roelof KG, Luo Y, Sintim HO, Lee VT (2012) A rapid assay for affinity and kinetics of molecular interactions with nucleic acids. Nucleic Acids Res 40: e48.

61. Lai Y, Destefano JJ (2012) DNA Aaptamers to Human Immunodeficiency Virus Reverse Transcriptase Selected by a Primer-Free SELEX Method: Characterization and Comparison with Other Aaptamers. Nucleic Acid Ther.

62. Christen B, Christen M, Paul R, Schauerte A, Jenal U (2005) Identification and Characterization of a Cyclic Di-GMP-Specific Phosphodiesterase and Its Allosteric Control by GTP. Journal of Biological Chemistry 280: 30829–30837.

63. DeStefano JJ, Cristofaro JV (2006) Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res 34: 130–139.

64. DeStefano JJ, Nair GR (2008) Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides 18: 133–144.

65. Tamayo R, Pratt JT, Camilli A (2007) Roles of cyclic diguanidylate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 61: 131–148.

66. Jena U, Malone J (2006) Mechanism of cyclic-di-GMP signaling in bacteria. Annu Rev Genet 40: 385–407.

67. Cotter PA, Stühler S (2007) c-di-GMP-mediated regulation of virulence and biofilm formation.Curr Opin Microbiol 10: 17–23.

68. Fiedler H, Fuchs MJ, Schauerte A, Jenal U (2006) Mechanism of cyclic-di-GMP signaling in bacteria. Annu Rev Genet 40: 385–407.

69. Cotter PA, Stühler S (2007) c-di-GMP-mediated regulation of virulence and biofilm formation. Curr Opin Microbiol 10: 17–23.

70. Sonderegger H, Shikuma NJ, Yildiz FH (2012) You’ve come a long way: c-di-GMP signaling. Curr Opin Microbiol 15: 140–146.

71. Merighi M, Lee V,Hyodo M, Hayakawa Y, Lory S (2007) The second messenger bio(3’,5’)-cyclic-GMP and its Piz domain-containing receptor Alg44 are required for alginate biosynthesis in Pseudomonas aeruginosa. Mol Microbiol 65: 876–895.

72. Amikam D, Galperin MY (2006) Piz domain is part of the bacterial c-di-GMP binding protein. Bioinformatics 22: 3–6.